Introduction
============

Dementia with Lewy bodies (DLB) is considered the second most common form of dementia after Alzheimer's disease (AD).[@b1-ndt-15-543] Aarsland et al[@b2-ndt-15-543] reported similar results of the proportion of DLB in a cohort study (AD, 65%; DLB, 20%). DLB is often misdiagnosed as AD or parkinsonism-related dementia. The core clinical features of DLB include neuropsychiatric and parkinsonian motor symptoms as well as cognitive impairment characterized by deficits in attention, executive function, and visual perception.[@b1-ndt-15-543] Fluctuating cognition, hallucinations, and delusions are major sources of difficulty and distress for both patients and caregivers.[@b3-ndt-15-543]

Aripiprazole is a second-generation atypical antipsychotic which has been approved for schizophrenia, mania, or mixed episodes associated with bipolar I disorder and as an adjunctive treatment for major depressive disorder.[@b4-ndt-15-543] The proposed mechanism of action for its efficacy is a combination of partial agonistic activity at D2 and 5-HT1A receptors and antagonistic activity at 5-HT2A receptors.[@b5-ndt-15-543] Furthermore, aripiprazole is presumed to have a weight gain, sedation, elevated serum prolactin levels, or prolongation of the heart rate-corrected QT interval on electrocardiography.[@b6-ndt-15-543] The QT interval represents the time from the onset of ventricular depolarization to completion of repolarization, and prolongation has been associated with ventricular arrhythmias that may trigger ventricular fibrillation and sudden death.

Although there have been several reports on the efficacy of treatments for psychotic symptoms in patients with DLB, little is known regarding the treatment effects of aripiprazole. In this article, we describe our retrospective, open-label experience with aripiprazole for the treatment of psychotic symptoms in patients with DLB.

Patients and methods
====================

We recruited consecutive nonselected patients from our institution. Eleven patients who met the consensus diagnostic criteria for DLB participated in this study,[@b1-ndt-15-543] including two men and nine women. Their average age was 76 years (range, 65--84 years). The patients had experienced persistent or intermittent delusions, hallucinations, or both for at least 1 month before enrolment in the study. Patients were accompanied by caregivers who routinely remained with them, provided information on this study, and assisted with treatment compliance. Patients who improved with environmental coordination and/or dementia medications and those who had schizophrenia, or brain damage, or a score of 25 or more on the Mini-Mental State Examination (MMSE) Scale were excluded. This study was approved by the institutional review board and ethical committee of Akita University Graduate School of Medicine. All patients or their families provided written informed consent before entering this study. This study was conducted according to the principles expressed in the Declaration of Helsinki.

Aripiprazole was initiated at a low dose (3 or 6 mg/day) and titrated to higher doses at 2-week intervals or more rapidly, based on the investigator's judgment, if the patient showed insufficient clinical response. Reductions from higher doses were permitted for tolerability ([Table 1](#t1-ndt-15-543){ref-type="table"}). The maximum dose of aripiprazole was 30 mg/day, as defined in Japan. The patients' use of medications prior to aripiprazole administration was not changed throughout this trial.

The patients' clinical status was assessed at baseline and 2, 4, 8, and 10 weeks later using the Neuropsychiatric Inventory (NPI), Clinical Global Impression-Severity (CGI-S), and Brief Psychiatric Rating Scale (BPRS) to measure psychotic symptoms. The Simpson--Angus Scale (SAS) was used to measure parkinsonian symptoms, and the Clinical Dementia Rating (CDR) and MMSE scores were used to evaluate cognitive function. The NPI, CGI-S, and BPRS scores were compared between baseline and each assessment point and between each assessment point and the previous one with Tukey's test. The SAS, CDR, and MMSE scores were compared between the baseline and the end point with a Wilcoxon signed-rank test. Statistical analyses were performed using the Statcel3 software (OMS Publishing, Saitama, Japan) with the significance level at 5%.

Results
=======

Patient characteristics are outlined in [Table 2](#t2-ndt-15-543){ref-type="table"}. Nine of the 11 patients (81.8%) completed the 10-week study. Reasons for withdrawal included hypersalivation (case 5) and drug denial due to lack of appetite (case 10). The mean dose of aripiprazole at the end point was 10.3 mg/day (range, 6--12 mg/day). There were no significant differences in the mean NPI, BPRS, CGI-S, and the median SAS, CDR, and MMSE scores between outpatients and inpatients at baseline. The mean NPI and BPRS scores decreased until the fourth week after the initiation of the aripiprazole treatment. The mean scores of NPI and BPRS significantly decreased at each assessment point compared to the previous one (*P*\<0.01). After 4 weeks, improvements slowed and continued without a significant decrease ([Figure 1](#f1-ndt-15-543){ref-type="fig"}). The mean CGI-S score significantly decreased until the eighth week (*P*\<0.01). The mean scores of CGI-S significantly decreased at each assessment point compared to the previous one (*P*\<0.01). The median SAS and MMSE scores significantly improved at the study end point compared to the baseline (*P*\<0.05). The median CDR score did not significantly decrease ([Table 3](#t3-ndt-15-543){ref-type="table"}).

Discussion
==========

In the present study, we found that aripiprazole reduced psychotic symptoms in patients with DLB. Although Mintzer et al[@b7-ndt-15-543] reported that aripiprazole, at 10 mg/day and 15 mg/day, was effective in reducing the symptoms of psychosis in patients with AD, to the best of our knowledge, this is the first report of aripiprazole's effectiveness in reducing psychotic symptoms in DLB. However, numerous other medications have been studied with regard to DLB. Lee et al[@b8-ndt-15-543] and Allen et al[@b9-ndt-15-543] reported a favorable response to treatment with 0.5--5 mg risperidone per day for the psychotic and behavioral symptoms of DLB. Takahashi et al[@b10-ndt-15-543] described that quetiapine was effective for coping with psychotic symptoms and aggressive behaviors in patients with DLB. Some reports have suggested that donepezil is effective for the treatment of psychotic and behavioral symptoms in DLB.[@b3-ndt-15-543],[@b11-ndt-15-543] In the present study, the mean NPI and BPRS scores significantly decreased until the fourth week after the initiation of the aripiprazole treatment (mean dose, 9.3 mg/day), after which the psychotic symptoms stabilized. The mean CGI-S score significantly decreased until the eighth week, after which the psychotic symptoms stabilized. These results indicate that improvement was shown in the initial 4-week period, after which the psychotic symptoms stabilized.

The most common side effects reported with aripiprazole were headache, insomnia, agitation, and anxiety. Marder et al[@b12-ndt-15-543] reported that discontinuation due to side effects occurred at an incidence rate of 7%. We had to discontinue aripiprazole treatment in 2 of our 11 patients because of hypersalivation (case 5) and drug denial and a lack of appetite (case 10). Both these reasons for the withdrawal of the aripiprazole treatment were mild in severity. In terms of motoric improvements, there was no significant median baseline end point change in the SAS after aripiprazole treatment. Aripiprazole has a high 5HT2/D2 ratio and may therefore carry a low risk of extrapyramidal syndrome (EPS).[@b13-ndt-15-543] This has been concluded based on several reports that have shown that the incidence of EPS-related side effects is low in aripiprazole treatments.[@b11-ndt-15-543],[@b14-ndt-15-543],[@b15-ndt-15-543] In our study, aripiprazole was found to be safe and well tolerated for the treatment of patients with DLB.

In the study of aripiprazole in AD by De Deyn et al,[@b14-ndt-15-543] only minimal mean changes in the MMSE score were observed from the baseline to the end point (aripiprazole, −0.81; placebo, −0.53; *P*\<0.001). Other AD studies have shown that the aripiprazole and placebo groups did not significantly differ in mean change in MMSE score at the end point.[@b11-ndt-15-543],[@b15-ndt-15-543] In contrast, several observational studies have shown that aripiprazole improves cognitive impairment in patients with schizophrenia.[@b16-ndt-15-543]--[@b19-ndt-15-543] In the present study, we demonstrated a significantly higher median MMSE score at the end point of the study compared to the baseline. This finding suggests that aripiprazole improved cognitive impairment in patients with DLB.

Our study was open label, and several factors disallow drawing definitive conclusions based on the present findings. The starting dose of aripiprazole and the titration schedule were not standardized. Although we recruited from consecutive patients, participants in this study consisted of predominantly women. It might be raise referral bias. The small sample size and lack of control group were also limitations of this study.

Conclusion
==========

Aripiprazole may be effective and well tolerated for the treatment of psychotic symptoms in patients of DLB, but further placebo-controlled double-blind trials, with larger number of patients, are needed to confirm this observation.

The abstract of this paper was presented at the 24th European Congress of Psychiatry as a poster presentation with interim findings. The poster's abstract was published in "Poster Abstracts" in European Psychiatry (<http://www.jscnp.org/> en/abstracts/19/19th Abstracts.pdf).
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###### 

Patients' aripiprazole doses

  Case   Dose of aripiprazole (mg/day)                            
  ------ ------------------------------- ----- ----- ----- ------ ------
  1      6                               6     12    12    12     12
  2      3                               3     6     9     12     12
  3      3                               3     6     6     9      9
  4      3                               3     6     9     12     12
  5      3                               3     6     --    --     --
  6      3                               3     6     6     6      6
  7      3                               3     6     6     6      6
  8      6                               6     12    12    12     12
  9      6                               6     12    12    12     12
  10     3                               3     --    --    --     --
  11     6                               6     12    12    12     12
  Mean   4.1                             4.1   8.4   9.3   10.3   10.3

###### 

Patient characteristics

  Case   Sex   Age (years)   Category of DLB   Stage      Concomitant medication   Complication of mental illness   Inpatient/outpatient
  ------ ----- ------------- ----------------- ---------- ------------------------ -------------------------------- ----------------------
  1      F     78            Probable          Moderate   Valproic acid            MDI                              Inpatient
  2      F     65            Probable          Severe     Clonazepam               RBD                              Outpatient
  3      F     84            Probable          Moderate   Benzodiazepine           D                                Outpatient
  4      M     83            Probable          Moderate   Clonazepam               RBD                              Outpatient
  5      F     83            Probable          Moderate   --                       MDI                              Outpatient
  6      F     75            Probable          Moderate   --                       --                               Outpatient
  7      F     78            Probable          Severe     --                       --                               Outpatient
  8      M     73            Probable          Moderate   Maprotiline              D                                Inpatient
  9      F     72            Probable          Moderate   Benzodiazepine           MDI                              Inpatient
  10     F     75            Probable          Severe     --                       --                               Inpatient
  11     F     74            Probable          Moderate   --                       MDI                              Inpatient

**Note:** Stage, based on baseline MMSE scale (severe, 0--9; moderate, 10--19; mild, 20--23).

**Abbreviations:** D, depression; DLB, dementia with Lewy bodies; F, female; M, male; MDI, manic-depressive illness; MMSE, Mini-mental State Examination; RBD, rapid eye movement sleep behavior disorder.

###### 

Median SAS, CDR, and MMSE scores (range) of the patients who completed the study

  Measure                                          Baseline     10 weeks      *P*-value
  ------------------------------------------------ ------------ ------------- -----------
  SAS[a](#tfn3-ndt-15-543){ref-type="table-fn"}    9 (4--14)    6 (4--9)      \<0.05
  CDR[a](#tfn3-ndt-15-543){ref-type="table-fn"}    2 (1--3)     1 (1--2)      NS
  MMSE[a](#tfn3-ndt-15-543){ref-type="table-fn"}   15 (9--19)   17 (12--21)   \<0.05

**Note:**

Wilcoxon signed-rank test.

**Abbreviations:** CDR, Clinical Dementia Rating; MMSE, Mini-mental State Examination; NS, not significant; SAS, Simpson--Angus Scale.
